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Keratoconus-susceptibility gene identification by
corneal thickness genome-wide association study
and artificial intelligence IBM Watson
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Nobuhisa Mizuki3, Akitaka Tsujikawa1, Kenji Yamashiro 1,8 & The Nagahama Study Group*
Keratoconus is a common ocular disorder that causes progressive corneal thinning and is the
leading indication for corneal transplantation. Central corneal thickness (CCT) is a highly
heritable characteristic that is associated with keratoconus. In this two-stage genome-wide
association study (GWAS) of CCT, we identified a locus for CCT, namely STON2 rs2371597
(P= 2.32 × 10−13), and confirmed a significant association between STON2 rs2371597 and
keratoconus development (P= 0.041). Additionally, strong STON2 expression was observed
in mouse corneal epithelial basal cells. We also identified SMAD3 rs12913547 as a sus-
ceptibility locus for keratoconus development using predictive analysis with IBM’s Watson
question answering computer system (P= 0.001). Further GWAS analyses combined with
Watson could effectively reveal detailed pathways underlying keratoconus development.
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Keratoconus is a common, bilateral, noninflammatory typeof corneal degeneration, affecting one out of every 375people in the general population1, and is a major indica-
tion for corneal transplantation in developed countries2–4. Ker-
atoconus is a progressive eye disease characterised by an
asymmetrical conical protrusion due to focal thinning of the
cornea, which causes variable and severe visual disturbances.
Thus, patients with severe keratoconus usually present with thin
corneas, although not all patients with thin corneas develop the
disease.
Although previous genome-wide association studies (GWASs)
were performed with keratoconus patients, no genetic region with
a significant genome-wide association has been identified thus
far5–7. Most of keratoconus-susceptibility genes were identified
through a large meta-GWAS of central corneal thickness (CCT),
because CCT is closely associated with keratoconus and is highly
heritable trait8–11. For example, Lu et al. conducted a GWAS on
CCT (n= 20,020), screened for associations between 26 CCT-
associated loci and keratoconus (ncase= 874, ncontrol= 6085), and
identified six loci associated with keratoconus susceptible12.
When the sample size of patients with disease is limited, this
intermediate phenotype strategy is reasonable because it is less
affected by multiple testing correction, when compared to a
simple GWAS. However, where possible, it is preferable to rea-
sonably narrow down the number of candidate genes that are
screened, in order to avoid ‘the curse of multiplicity’. Indeed,
although a recent large meta-GWAS of CCT (n= 25,910) iden-
tified multiple additional CCT-associated loci, no novel
keratoconus-susceptible genes were identified through sequential
screening (ncase= 933, ncontrol= 5946)13. In addition, pathway
analysis of keratoconus has not been performed because of the
lack of reliable GWASs of keratoconus. To reveal the specific role
of various genes in keratoconus development, it may be impor-
tant to identify susceptibility genes with relatively smaller effect
size, which cannot be identified through large sample size GWAS
studies14.
In this study, we used the latest artificial intelligence technol-
ogy, IBM’s Watson for Drug Discovery (WDD), to select candi-
date genes from the results of our newly performed GWAS on
CCT. WDD, which has been configured to support life science
research, can help in understanding and identifying relationships
between molecules/genes, using various types of enormous
datasets from structured databases and PubMed database15,16. To
identify new keratoconus-susceptibility loci, we performed a
traditional two-stage GWAS on CCT using a Japanese
community-based cohort, and assessed the association of CCT-
susceptibility loci with keratoconus occurrence. Further, we
assessed new keratoconus-susceptibility genes derived from the
combination of GWAS results and WDD.
Results
Two-stage GWAS of CCT in Japanese patients. To investigate
and identify genetic loci associated with CCT, the average CCT in
both eyes was used as the dependent variable for genome-wide
quantitative trait locus (QTL) analyses. We included the age, sex,
average axial length of both eyes, and the first principal compo-
nent as covariates. An inflation factor (λGC) of 1.065 indicated
good control of the study population substructure (Supplemen-
tary Fig. 1). We also found that inclusion of additional PCs
minimally altered the findings.
During the first stage with 3584 participants, we identified two
single-nucleotide polymorphisms (SNPs), namely STON2
rs2371597 (β= 5.35, P= 1.91 × 10−11) and FNDC3B rs4894538
(β=−4.13, P= 1.90 × 10−8), which exceeded genome-wide
significance (Fig. 1 and Table 1). Since FNDC3B rs4894538 was
in strong linkage disequilibrium with rs4894535 (R2= 0.991 in
the discovery set), which is an established SNP associated with
CCT and keratoconus, we only carried STON2 rs2371597 forward
to the replication stage. In the replication stage, we analysed 2942
participants and found that STON2 rs2371597 showed a
significant association with CCT (β= 2.95, P= 3.58 × 10−4).
Meta-analysis of the discovery and replication sets further
confirmed a robust association of STON2 rs2371597 with CCT
(βmeta-Japanese= 4.20, Pmeta-Japanese= 2.32 × 10−13).
The baseline characteristics of the participants and SNPs that
showed P-values of <1.0 × 10−4 are shown in the Supplementary
Table 1 and Supplementary Data 1.
Replication with patients of other ethnicities. To confirm the
association between STON2 rs2371597 and CCT in individuals
with other ethnicities, we conducted trans-ethnic replication
analyses using three different cohorts comprised of Malay,
Chinese, and Indian subjects (N= 2510, 2469, and 2508,
respectively) (Table 2). In all cohorts, the rs2371597 C allele
was associated with increased CCTs (β= 2.14, P= 0.0406,
Malay cohort; β= 2.44, P= 0.021, Chinese cohort; β= 1.56,
P= 0.130, Indian cohort), which was in agreement with the
data from the Japanese cohort. Thus, meta-analysis of the data
from all ethnic groups revealed a strong association between
rs2371597 and CCT (Pmeta-all= 2.18 × 10−4). Additionally,
publicly available GWAS data enabled us to discover an asso-
ciation of the STON2 rs2371597 C allele with increased CCTs in
a Latino population (P= 6.12 × 10−3, Table 2).
STON2 rs2371597
FNDC3B rs4894538
Fig. 1 Manhattan plot of QTL data from our GWAS of CCT. The plot shows −log10-transformed P-values for all SNPs adjusted for age, sex, average axial
length in both eyes, and the first principal component. The horizontal line represents the genome-wide significance threshold of 5.0 × 10−8, and the lower
dashed line represents the threshold of 1.0 × 10−4 to identify candidate genes for Watson Drug Discovery analysis.
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Association of previously reported CCT-associated loci with
CCT. We also evaluated the association of 93 previously reported
CCT-susceptible SNPs from 57 genetic regions in our discovery
GWAS, using 3584 samples10,11. Of these SNPs, 53 were included
in our discovery dataset, and 30 (56.6%) from 18 genetic regions
showed an association with CCT with the same effect directions
reported previously (P < 0.05, Supplementary Data 2). After
Bonferroni’s correction, 14 of the 53 SNPs (26.4%) showed a
significant association with CCT. Additionally, we assessed the
associations of SNPs with the lowest P-value in the 48 genetic
regions. We found 39 of the top 48 SNPs (81.3%) had a P-value of
<0.05, and 16 SNPs (33.3%) showed significant associations with
CCT after Bonferroni’s correction (Supplementary Data 2).
Association of STON2 with keratoconus. To evaluate the pos-
sible association between STON2 rs2371597 and keratoconus, we
conducted a case-controlled study using 179 keratoconus
patients, regardless of age, sex, or physical impairment, from the
Yokohama City University and 11,084 Japanese healthy controls.
This analysis revealed that minor-allele frequency (MAF) at
rs2371597 C was significantly high in keratoconus patients than
that in controls (MAFkeratocnus= 0.293, MAFcontrols= 0.246, odds
ratio [OR] (95% confidence interval [CI])= 1.27 (1.01–1.60), P=
0.041).
Expression of STON2 in human tissues and in the mouse
cornea. A search of a publicly available expression quantitative
trait loci analysis (eQTL) database revealed that rs2371597 was
significantly associated with STON2 expression (GTEx Portal;
https://gtexportal.org/home/). A multi-tissue eQTL plot revealed
that the normalised effect size (NES) of rs2371597 on STON2
expression was strongest in the skeletal muscle (NES=−0.189,
P= 1.3 × 10−8; Fig. 2, https://www.gtexportal.org/home/snp/
rs2371597) in which collagen plays an important role in pro-
viding its tensile strength and elasticity. However, data on the
association of rs2371597 with gene expression in human corneal
tissue were not available.
Our immunohistochemical study of mouse corneas showed
that STON2 was expressed in the corneal epithelial cell layer
(Fig. 3). Our results demonstrated that strong STON2 expression
mainly occurred in basal cells rather than superficial cells in the
corneal epithelium. In the stroma and endothelium layer, only
minimal STON2 expression was observed.
Predictive analysis using the WDD system. WDD predictive
analysis scores and visualisation of the relationships between
‘teaching genes’ and candidate genes (based on searching millions
of Medline abstracts in PubMed [accessed on March 1st, 2018], as
described in the Methods section). The similarity score (i.e. the
degree of similarity to ‘teaching genes’) of each candidate gene is
shown in Supplementary Table 2. The tree plot and scatter plot
results are shown in Figs. 4 and 5. Three major streams were
observed, and STON2 was part of the FOXO1–SMAD3 stream
(Fig. 4).
We focused on candidate genes within the FOXO1–SMAD–
STON2 stream. Specifically, we selected seven keratoconus-
susceptibility genes (CDH13, SMAD3, ADAM12, CSMD1, NRXN1,
CPLX2, and WWOX) for further analysis. Among these candidate
genes, SMAD3 showed the highest similarity score when compared to
the ‘teaching genes’ (Supplementary Table 3). Since the SMAD3
rs11333560 genotype was not available in the Tohoku Medical
Megabank Project, we instead employed a proxy SNP (rs12913547 in
SMAD3). The SMAD3 rs12913547 T allele was significantly
associated with an increased risk for keratoconus development after
Bonferroni’s correction (OR (95% CI)= 1.44 (1.16–1.80), P= 0.001,
Table 3). CPLX2 rs4242187 tended to show an association with
keratoconus, but the association was not statistically significant (OR
(95% CI)= 0.70 (0.46–1.05), P= 0.082).
Discussion
In this study, we identified two keratoconus-susceptibility genes
by integrating conventional GWAS of CCT and artificial intelli-
gence, using the WDD platform. We found that the STON2
rs2371597 allele was significantly associated with CCT and ker-
atoconus, as well as significantly altered STON2 expression in
Table 2 Replication of the STON2 rs2371597 association with CCT.
SNP Chr Position Effect allele Cohort Ethnicity N Discovery stage
β SE P
rs2371597 14 81873377 C Nagahama Japanese 6526 4.20 0.573 2.32 × 10−13
C SiMES Malay 2510 2.14 1.045 0.0406
C SCES Chinese 2469 2.44 1.063 0.0215
C SINDI Indian 2508 1.56 1.028 0.130
C 4 collections Meta 14,013 3.17 0.415 2.18 × 10−14
C – Latino 3584 –a – 6.12 × 10−3
SE, standard error.
aThe effect direction was the same as those found with the other ethnicities.
Table 1 SNPs that showed genome-wide significant association with CCT in the discovery stages.
SNP Chr Position Effect allele EAF Gene Discovery stage Replication stage Meta-analysis
N β P N β P N β P
rs4894538 3 171999005 T 0.299 FNDC3B
(intron)
3584 −4.13 1.90 × 10−8 – – – – – –
rs2371597 14 81873377 C 0.242 STON2
(intron)
3584 5.35 1.91 × 10−11 2942 2.95 3.58 × 10−4 6526 4.20 2.32 × 10−13
Chr, chromosome; EAF, effect allele frequency; β, beta; P, P-value.
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human tissues. WDD analysis assisted in identifying another
keratoconus-susceptibility SNP, i.e. SMAD3 rs12913547. Con-
sidering that recent association analyses of keratoconus failed to
identify novel keratoconus-susceptibility genes despite their
large sample sizes5,6,13, the current approach of combining
GWAS and artificial intelligence data appears to have been quite
efficient.
We first conducted a conventional GWAS of CCT with trans-
ethnic replication. This analysis enabled us (1) to confirm STON2
as a susceptibility gene for CCT and (2) to show that our Japanese
population shared most of underlying genetic effects not only
with other Asian populations, but also with European and Latino
populations12,17. ZNF469 rs9938149, the most established CCT-
susceptibility SNP, was replicated in our GWAS (n= 3584, β=
−3.35, P= 7.45 × 10−3). The relatively high P-value was due to
its small MAF in Japanese subjects, compared to European ethnic
groups (MAFJapanese= 0.034, MAFEuropean= 0.349; data from the
1000 Genomes database).
We also identified STON2 rs2371597 (located at chromo-
some14q31) as a keratoconus-susceptibility SNP. STON2 was
previously identified as an endocytic adaptor dedicated to the
retrieval of surface-stranded synaptic vesicle proteins18. A pre-
vious genetic study reported that STON2 SNPs were associated
with CCT, but not with keratoconus development in Caucasians.
Therefore, as the prevalence of keratoconus is known to be higher
in the Asian population compared to Caucasians, we speculate
that the genetic and pathological background of keratoconus
differs between ethnicities. Moreover, as it is possible that certain
keratoconus-susceptibility genes identified in Asians are not
associated with keratoconus development in Caucasians, further
studies are required to compare the effect size of keratoconus-
susceptibility genes on keratoconus development across various
ethnicities, which will serve to reveal ethnical differences.
The eQTL data revealed that the effect size of rs2371597 on
STON2 expression was strongest in skeletal muscle, which is rich
Fig. 2 Multi-tissue eQTL-based comparison of the association between rs2371597 and STON2 expression. Multi-tissue eQTL plot generated by
performing an eQTL search of a publicly available database (GTEx Portal; https://gtexportal.org/home/). The effect size of rs2371597 on STON2





Fig. 3 Expression of STON2 in retinal ganglion cells of C57BL/6 mice.
Mouse corneal sections were immunostained with an antibody against
STON2 (green). The nuclei are counterstained with 40,6-diamidino-2-
phenylindole (blue) in the merged image. The upper portion of the panel
shows the corneal epithelium.
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in collagen, a protein that reportedly plays a key role in kerato-
conus pathogenesis. Although no previous reports have investi-
gated the expression of STON2 in human corneal tissue, we
speculate that STON2 may play an important role in keratoconus
development by interacting with extracellular matrix remodelling.
Our immunohistochemical staining results for STON2 are com-
patible with a previous histopathological study of keratoconus,
which showed that thinning of the corneal stroma, breaks in
Bowman’s layer, and degeneration of the corneal epithelium were
the characteristics of corneas in patients with keratoconus2,19.
STON2 might be associated with the vulnerability to physical
damage or immunological changes. Although biological studies
examining the role of STON2 in human corneal tissue are
required to prove our hypothesis, pathways involving STON2
may serve as targets for treating keratoconus by controlling basal
cell degeneration.
Through WDD, we identified SMAD3 as an additional
keratoconus-susceptibility gene (OR= 1.44 (1.16–1.80), P=
0.001), and CPLX2 as a future candidate gene for keratoconus-
susceptibility (OR= 0.70 (0.46–1.05), P= 0.082). SMAD3 is
known to play a significant role in the transforming growth
factor-β (TGF-β) signalling pathway, which may modulate
extracellular matrix (ECM) alterations in keratoconus20. Data
from a previous study showed TGF-β/SMAD3 signalling pro-
moted gluconeogenesis through an interaction with FOXO1,
which is an established keratoconus-susceptibility gene21. Further
studies of the roles of SMAD3, FOXO1, and TGF-β signalling in
keratoconus development are needed. In addition, CPLX2 is
another interesting target because (1) both CPLX2 and STON2
are reported to be associated with schizophrenia18,22, and (2)
comorbidity between schizophrenia and keratoconus was also
demonstrated previously23–26. We speculate that schizophrenia
and keratoconus employ shared underlying pathophysiological
processes, which would be another pathway apart from gluco-
neogenesis. We expect that the relationships between these two
diseases will be studied more in the future.
We expected that CCT-reducing alleles would be associated
with an increased risk of developing keratoconus, given the
Fig. 4 Tree plot of WDD-based predictive analysis. Nine teacher genes (green triangles) and 42 candidate genes (red circles) are shown, based on
predictive analysis with WDD. The relationships between the genes are visualised.
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known association between thin corneas and the disease. Indeed,
most CCT-reducing alleles have been associated with an
increased risk of keratoconus, and this was true for SMAD3
rs12913547 in the current study. However, with STON2, a CCT-
increasing allele led to increased keratoconus risk. Although this
finding was unexpected, such complex association patterns have
often been observed in previous studies. One example is that a
body fat-decreasing allele near IRS1 was also associated with
Table 3 Testing seven CCT-associated loci for keratoconus-susceptibility.
Gene Chr Position SNP Effect allele Control Keratoconus Odds ratio (95% CI) Pa
N EAF N EAF
NRXN1 2 50635086 rs13382330 C 8137 0.176 179 0.159 0.89 (0.67–1.19) 0.420
CPLX2 5 175244097 rs4242187 T 8150 0.097 179 0.070 0.70 (0.46–1.05) 0.082
CSMD1 8 2799288 rs143428993 A 8148 0.012 179 0.017 1.39 (0.61–3.14) 0.435
ADAM12 10 127905962 rs11244890 A 8156 0.211 179 0.196 0.91 (0.70–1.19) 0.491
SMAD3 15 67467507 rs12913547 T 8096 0.563 179 0.651 1.44 (1.16–1.80) 0.001b
WWOX 16 78430702 rs6564538 T 8156 0.110 179 0.117 1.07 (0.77–1.48) 0.680
CDH13 16 83650510 rs1035533 G 8150 0.190 179 0.201 1.07 (0.83–1.39) 0.594
Chr, chromosome; EAF, effect allele frequency; SNP, single-nucleotide polymorphism; CI, confidence interval.
aP-values derived using logistic-regression analysis.
bP-values are statistically significant after Bonferroni’s correction.
Fig. 5 Scatter plot of WDD-based predictive analysis. A scatter plot of genes was generated based on their distances in the literature. Nine teacher genes
(green triangles) and 42 candidate genes (red circles) are shown.
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adverse lipid profiles, and increased risks for coronary artery
disease and type-2 diabetes27–29. Another example is that the
most famous CCT-reducing SNP, rs9938149, located between
BANP and ZNF469, is known to decrease keratoconus risk12. We
anticipate that further research on ZNF469 and STON2 will reveal
pleiotropic effects for these genes in terms of corneal thickness
and the risk for keratoconus development.
We applied a approach, i.e. WDD, to screen for keratoconus-
susceptibility SNPs from thousands of potential CCT-
susceptibility SNPs. While we focused on seven genes out of 52
candidate genes (based on the predictive analysis results of
WDD), SNPs in only two genes showed a significant or marginal
association with keratoconus. Since the similarity score was cal-
culated based on Medline abstract searches in PubMed, genes that
have been more extensively studied tend to have higher scores.
We focused on genes located between ‘teacher genes’ and STON2
in this study to identify genes that were not sufficiently evaluated
in previous studies. Although CPLX2 (ranked number 16 by
Watson) showed a marginally significant association with kera-
toconus, only SMAD3 (with the highest similarity score) showed
a robust association with keratoconus. However, other genes with
a relatively high similarity score, such as CDH13 andMEIS1, were
not associated with keratoconus. Interestingly, CPLX2 and
SMAD3 were located next to teaching genes, whereas CDH13 and
MEIS1 were not. We speculate that the rank of the similarity
score may be an important index; however, the approach used to
rank scores needs to be improved. To identify disease-susceptible
genes with Watson, we propose that focusing on genes located
between and/or next to teaching genes may be important. Further
studies will be required to establish a method for combining
GWAS with Watson.
In summary, we identified two keratoconus-susceptibility loci,
STON2 and SMAD3, by integrating conventional GWAS and
artificial intelligence, using WDD. Cognitive-computing tech-
nology combined with GWAS can assist in identifying hidden
relationships among disease-susceptibility genes and potential
susceptibility genes, enabling more efficient interpretation of
GWAS results. We believe that the current approach can be
generalised for application to numerous other diseases. Since
samples from patients with a disease are more difficult to obtain
than samples from healthy individuals, which can be collected
through cohort studies, the current approach will prove parti-
cularly helpful in facilitating the exploration of disease-
susceptible genes.
Methods
Participants in the two-staged GWAS of CCT. For the two-staged GWAS, we
analysed data from healthy Japanese volunteers enrolled in the Nagahama Pro-
spective Cohort for Comprehensive Human Bioscience (the Nagahama Study). The
initial follow-up data were collected from 9850 participants between July 2013 and
February 2017; meanwhile data collected from 8289 participants (34–80 years of
age) between July 2013 and February 2016 were used for the CCT measurements.
All participants underwent ophthalmic examinations, including objective
determinations of the corneal thicknesses (TX-20P; Canon, Tokyo, Japan) and axial
lengths (IOLMaster; Carl Zeiss Meditec, Inc., Dublin, CA, USA). The study
participants comprised individuals with available DNA samples; CCTs for both
eyes; and information regarding the patient’s age, sex, and axial length of both eyes.
Of the participants, 84 who lacked CCT data for both eyes, 617 with a history of
intraocular surgery, and 480 who lacked axial length data for both eyes were
excluded. Of the remaining participants, samples from those who underwent
genome-wide SNP genotyping were used for the discovery GWAS, and remaining
subset of samples was used for the replication stage.
The Kyoto University Graduate School and Faculty of Medicine Ethics
Committee and the Nagahama Municipal Review Board of Personal Information
Protection approved the study protocol and the procedures used to obtain
informed consent (Kyoto University Graduate School and Faculty of Medicine
Ethics Committee approval number; G0278). All study procedures adhered to the
tenets of the Declaration of Helsinki. All participants were fully informed of the
purpose and procedures of the study, and written consent was obtained from each
participant. Patient records and information were anonymised prior to analysis.
Genome-wide SNP genotyping. Genomic DNA was extracted from peripheral
blood samples according to standard laboratory procedures. Genome-wide SNP
genotyping was performed on samples from 5299 participants. A series of Bead-
Chip DNA arrays, namely the HumanHap610 Quad (1818 samples), Huma-
nOmni2.5-4 (1606 samples), HumanOmni2.5-8 (375 samples), HumanOmni2.5 s
(671 samples), CoreExome24 (1,722 samples), and HumanExome (671 samples;
Illumina, San Diego, CA, USA) arrays, were used for the analysis. Some samples
were repeatedly genotyped using multiple kinds of DNA arrays.
Quality-control filters were used to remove poorly performing samples and SNP
markers. SNPs with a call rate of <99%, an MAF of <1%, and a significant deviation
from the Hardy–Weinberg equilibrium (P < 1.0 × 10−6) were excluded from
further statistical analysis. Samples with a call rate of <95% were excluded from the
analysis. Among the remaining participants, 636 were estimated to have a first- or
second-degree kinship within this population (pi-hat > 0.35, PLINK ver. 1.90
[https://www.cog-genomics.org/plink/1.9/]) and were excluded from the analysis.
Genotype imputation was performed using MACH software (http://www.sph.
umich.edu/csg/abecasis/MACH/tour/imputation.html), with a 1000 Genomes
dataset (phase 3, v5 release) serving as a reference panel. Imputed SNPs for which
R2 < 0.5 were excluded from the association analysis. Finally, 4,710,779 SNPs from
3584 individuals were used for the discovery stage analysis.
Replication genotyping for the GWAS of CCT. To conduct a replication study
for confirming genetic associations with CCT, genotypes of the remaining samples
from the Nagahama Study (n= 3422) were determined using commercially
available TaqMan SNP assays and the ABI PRISM 7700 system (Applied Biosys-
tems, Foster City, CA, USA). Fourteen patients without CCT data in both eyes, six
patients lacking axial length data for both eyes, and 460 patients with history of
intraocular surgery were excluded. Finally, 2942 samples were used for the repli-
cation stage analysis.
Trans-ethnic replication. All patients enrolled in the study provided informed
consent, and ethical approval was granted by Singapore Malay Eye Study (SiMES)
group, the SingHealth Centralized Institutional Review Board (SCES), and the
Singapore Indian Eye Study (SINDI) group. For the trans-ethnic replication stage,
we included three Asian cohorts, namely the SiMES, SCES, and SINDI cohorts,
which consisted of Malay (n= 2510), Chinese (n= 2469), and Indian (n= 2508)
subjects, respectively. We also included publicly available data on a Latino popu-
lation (n= 3584). Detailed information and the sample-collection methods for
these cohorts can be found in the Supplementary Table 4 and Supplementary Note
and in a previous publication17.
Statistics and reproducibility. Genome-wide linear-regression analysis was con-
ducted for the average CCT in both eyes in the discovery set of the Nagahama
Cohort (N= 3584). This regression framework enabled us to adjust for covariates,
such as age, sex, the average axial length in both eyes, and the first principal
component. In the replication analysis with data from the SiMES (N= 2510), SCES
(N= 2469), and SINDI (N= 2508) cohorts, we performed association testing
under an additive model to examine the effect of the risk allele, while adjusting for
the age, sex, and at least the first five principle components. Experiment-wide
significance in the discovery stage was set at P < 5.0 × 10−8. All meta-analyses were
performed using an inverse variance weighted fixed effect model. Thereafter, dif-
ferences were considered statistically significant at P < 0.05. Deviations in genotype
distributions from the Hardy–Weinberg equilibrium were assessed by performing
Chi-squared tests. These statistical analyses were performed using R software (R
Foundation for Statistical Computing, Vienna, Austria; available at http://www.
rproject.org/, version 3.5.2) and PLINK software, version 1.90 (https://www.cog-
genomics.org/plink/1.9/).
Association of identified keratoconus-susceptibility gene with keratoconus.
To investigate the association between identified gene and keratoconus, we per-
formed a case-control analysis using data from 179 patients with keratoconus from
Yokohama City University and pooled the data of 9589 Japanese healthy control
subjects from Yokohama City University, Nagahama Cohort and Tohoku Medical
Megabank Project30,31 A detailed description of these cohorts and the genotyping
methods used are provided in the Supplementary Note. Briefly, both cases and
controls were recruited from the Yokohama City University, and genotyped using
the same genotyping platform, OmniExpress, and imputed using the same pipe-
lines. Control samples from the Nagahama Cohort were genotyped as described
above. Control samples from the Tohoku Medical Megabank Project were derived
from a publicly available database. Differences in the genotype distributions of
these cohorts were tested using the Cochran–Armitage test. P < 0.05 was set as the
threshold of statistical significance.
Immunohistochemical staining. To confirm the expression of identified gene, we
conducted immunohistochemical staining with the corneas of normal adult
C57BL/6 mice. After each mouse was sacrificed, the eyes were enucleated and fixed
with 4% paraformaldehyde in 0.1 M PB for 20 min. Expression in the cornea was
examined in vertical sections. For this purpose, the eyes were cryoprotected in a
sucrose gradient (10 and 30% w/v sucrose in 0.1 M PB), and 13-μm cryostat
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sections were cut. The sections were blocked for 1 h in a solution containing 10%
normal goat serum (Millipore), 0.3% Triton X-100 (Bio-Rad, Hercules, CA, USA),
and 0.1 M PB. The sections were incubated overnight at 4 °C with a primary rabbit
anti-human STON2 antibody (catalogue number NBP1-90658; Novus Biologicals,
LLC), diluted 1:10 in blocking solution. Subsequently, the sections were incubated
for 1 h with a secondary Alexa Fluor 488-conjugated goat anti-rabit IgG antibody
(catalogue number A-11005; Invitrogen, Eugene, OR, USA). All incubation steps
were performed at 4 °C. All images were obtained using a Keyence BZ-9000
microscope.
Predictive pathway analysis using the WDD system. WDD is one of the most
famous cognitive-computing systems. The details of the WDD predictive analysis
algorithm are described elsewhere15; thus, the system is introduced briefly below.
WDD is configured to support life sciences research and extracts text features from
medical literature to identify new connections between entities of interest, such as
genes and diseases. From these documents, Watson can create semantic connec-
tions between a known set of genes associated with keratoconus and candidate
genes. WDD can also rank the candidate genes by their degrees of similarity to the
known set, using a graph-diffusion algorithm.
To detect additional keratoconus-susceptibility loci and infer pathways
associated with keratoconus, we performed WDD predictive analysis. Eight
previously reported keratoconus-susceptibility genes (FNDC3B, COL5A1, FOXO1,
MPDZ, NF1B, RXRA, BANP, and ZNF469) and the newly identified keratoconus-
susceptibility gene was input as a ‘teaching gene’12,32,33.
The candidate genes were selected as follows. First, from 1215 SNPs with a P-
value of <1.0 × 10−4 in the discovery GWAS (Supplementary Data 1), we selected
745 SNPs that were located within a gene. These SNPs were distributed within 53
genomic regions. Second, genes that had already been input as ‘teaching genes’ and
genes that had never been mentioned previously in the literature were
automatically excluded, resulting in the exclusion of three and eight genes as
candidates, respectively. Finally, 42 genes were selected as candidate genes. This
process is summarised in Supplementary Table 2.
Based on the predictive analysis results of WDD, we selected possible
keratoconus-susceptibility genes with respect to identified gene and assessed the
associations between those genes and keratoconus. For association studies with
keratoconus, we principally selected the top SNP within the genes. If genotype data
of the SNP of interest was not available in any of the control cohorts, we employed
proxy SNPs instead. An association study was performed using data from 179
patients with keratoconus and pooled data from 6651 healthy control subjects. The
Cochran–Armitage test and Bonferroni’s correction were applied for statistical
assessments. The nominal P-value threshold was set to 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The complete GWAS summary data can be visualised at figshare (https://figshare.com/
articles/dataset/CCT/12592529). The datasets generated during the current study are also
available from the corresponding author on reasonable request.
Code availability
IBM’s Watson for Drug Discovery was used to select candidate genes in the present study
(accessed on March 1st, 2018).
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